Egnite, Inc., a leading cardiovascular digital health company, has announced significant findings from its research on the real-world effects of clinical presentation in patients with moderate or greater aortic stenosis (AS) undergoing aortic valve replacement (AVR).
Presented by Dr. Philippe Généreux, Director of the Structural Heart Program at Morristown Medical Center’s Gagnon Cardiovascular Institute, at the Transcatheter Cardiovascular Therapeutics (TCT) conference and published in the Structural Heart Journal, the study examined data from over 2 million patients across 29 U.S. health systems.
The results revealed a substantial difference in two-year outcomes after AVR between asymptomatic patients and those with progressive valve syndrome (PVS) or acute valve syndrome (AVS). Asymptomatic patients experienced more than a threefold reduction in the risk of mortality and heart failure hospitalization compared to those with AVS, underscoring the life-saving potential of AVR prior to the onset of symptoms.
Key Findings:
- Clinical Presentation Before AVR:
- Asymptomatic: 14.0%
- PVS: 34.3%
- AVS: 51.7%
- 2-Year Post-AVR Outcomes:
- All-Cause Mortality:
- Asymptomatic: 5.8%
- PVS: 7.6%
- AVS: 17.5%
- Hospitalization for Heart Failure:
- Asymptomatic: 11.1%
- PVS: 19.0%
- AVS: 41.5%
Dr. Généreux emphasized the importance of these findings, noting that while the absence of symptoms was traditionally viewed as a safety indicator, the study shows the prevalence of acute valve syndrome in patients undergoing AVR. He highlighted that intervention before symptoms emerge could greatly benefit patients. Those with acute valve syndrome, such as syncope or severe heart failure, faced a threefold increase in mortality two years post-AVR. He warned, “One out of six patients will die at two years if we wait for acute or advanced symptoms before performing AVR.”
About Egnite, Inc.
Egnite is a data-centric digital health company dedicated to improving societal health through innovative cardiovascular solutions. Utilizing AI-driven algorithms and big data, egnite generates actionable insights for healthcare, enhancing the role of data in critical decision-making. Based in Aliso Viejo, California, the company collaborates with leading hospitals and life sciences organizations to transform cardiovascular care delivery.
